Dragana Kopanja Selected Research

Complementation Group E Xeroderma Pigmentosum

6/2013	DDB2 suppresses epithelial-to-mesenchymal transition in colon cancer.
6/2009	DDB2 decides cell fate following DNA damage.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Dragana Kopanja Research Topics

Disease

5	Neoplasms (Cancer) 01/2022 - 01/2012
2	Complementation Group E Xeroderma Pigmentosum 06/2013 - 06/2009
2	Colonic Neoplasms (Colon Cancer) 06/2013 - 02/2013
2	Xeroderma Pigmentosum (Kaposi's Disease) 06/2013 - 01/2008
1	Hepatocellular Carcinoma (Hepatoma) 01/2019
1	Liver Neoplasms (Liver Cancer) 01/2018
1	Liver Diseases (Liver Disease) 01/2018
1	Lymphoma (Lymphomas) 05/2013
1	Sarcoma (Soft Tissue Sarcoma) 05/2013
1	Lung Neoplasms (Lung Cancer) 02/2013
1	Carcinogenesis 12/2009

Drug/Important Bio-Agent (IBA)

4	Proteins (Proteins, Gene)FDA Link 02/2013 - 01/2008
3	Forkhead Transcription Factors (Forkhead Box Proteins)IBA 01/2022 - 05/2013
3	DNA-Binding Proteins (DNA Binding Protein)IBA 06/2013 - 06/2009
1	Messenger RNA (mRNA)IBA 01/2022
1	RNA (Ribonucleic Acid)IBA 01/2022
1	Tumor Suppressor Protein p14ARF (p14ARF)IBA 01/2018
1	Transcription Factors (Transcription Factor)IBA 01/2017
1	SurvivinIBA 05/2013
1	Peptides (Polypeptides)IBA 05/2013
1	phenethyl isothiocyanate (PEITC)IBA 02/2013
1	Reactive Oxygen Species (Oxygen Radicals)IBA 02/2013
1	A-Form DNA (A-DNA)IBA 02/2013
1	Ubiquitin-Protein Ligases (Ubiquitin-Protein Ligase)IBA 01/2008

Therapy/Procedure

3	Therapeutics 01/2018 - 02/2013